Annual Report 2021

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2021 83 The United Laboratories International Holdings Limited Annual Report 2021 5. REVENUE AND SEGMENT INFORMATION (Continued) (i) Disaggregation of revenue from contracts with customers For the year ended 31 December 2021 Intermediate Bulk Finished products medicine products Total Elimination Consolidated RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 Types of products – 6-APA 957,578 – – 957,578 – 957,578 – Antibiotics products – 3,960,900 2,305,244 6,266,144 – 6,266,144 – Insulin Products – – 1,342,450 1,342,450 – 1,342,450 – Others 742,759 7,675 386,832 1,137,266 – 1,137,266 Revenue from contracts with customers 1,700,337 3,968,575 4,034,526 9,703,438 – 9,703,438 Inter-segment sales 1,684,837 585,413 – 2,270,250 (2,270,250) – Segment revenue 3,385,174 4,553,988 4,034,526 11,973,688 (2,270,250) 9,703,438